RESUMO
Inflammation is a component of glioma microenvironment. PTX3 is a component of the humoral arm of innate immunity and a candidate marker of inflammation. In the present study we assessed the expression of PTX3 in gliomas by immunohistochemistry. PTX3 expression differed across low and high-grade tumors based on histopathological diagnosis and clinical severity, positively correlating with tumor grade and severity. In a multivariate logistic regression model, only the PTX3 score was significantly associated with the presence of a high-grade tumor. Thus, PTX3 may represent a new marker of cancer-related inflammation and glioma malignancy.
Assuntos
Neoplasias Encefálicas/imunologia , Proteína C-Reativa/imunologia , Encefalite/imunologia , Glioblastoma/imunologia , Oligodendroglioma/imunologia , Componente Amiloide P Sérico/imunologia , Adulto , Antígenos CD/metabolismo , Antígenos de Diferenciação Mielomonocítica/metabolismo , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/patologia , Proteína C-Reativa/genética , Proteína C-Reativa/metabolismo , Metilases de Modificação do DNA/genética , Enzimas Reparadoras do DNA/genética , Encefalite/metabolismo , Encefalite/patologia , Feminino , Glioblastoma/metabolismo , Glioblastoma/patologia , Humanos , Modelos Logísticos , Macrófagos/imunologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Gradação de Tumores , Oligodendroglioma/metabolismo , Oligodendroglioma/patologia , Valor Preditivo dos Testes , Prognóstico , Componente Amiloide P Sérico/genética , Componente Amiloide P Sérico/metabolismo , Índice de Gravidade de Doença , Proteínas Supressoras de Tumor/genéticaRESUMO
The chemokine receptor CX3CR1 and its cognate ligand CX3CL1 (also known as fractalkine), are involved in central nervous system pathophysiology, in particular, in the cross-talk between neurons and microglia. It was therefore important to investigate the expression of CX3CR1 in gliomas, the most frequently occurring, malignant brain tumors. In a consecutive series of 70 patients with primary, central nervous glial tumors, CX3CR1 was highly expressed in tumor cells as assessed by RT-PCR mRNA and protein levels, and by immunohistochemistry, while the corresponding normal cells were negative. Receptor immuno-positivity did not correlate with histology, grade, chromosomal (1p,19q) deletion, or with methylation of the DNA repair gene promoter MGMT (O6-methylguanine-DNA methyltransferase). Thus, CX3CR1 expression is a frequent event in gliomas, irrespective of tumor classification and clinical severity. The molecular basis underlying CX3CR1 up-regulation and its functional biological significance remain to be determined.